Legal Representation
Attorney
Robert S. Broder
USPTO Deadlines
Next Deadline
2074 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20250916)
Due Date
September 16, 2031
Grace Period Ends
March 16, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
25 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 16, 2025 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Sep 16, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Sep 16, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 29, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 29, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 23, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 24, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 30, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 30, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 30, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 3, 2025 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Apr 15, 2025 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Apr 15, 2025 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Apr 12, 2025 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Mar 25, 2025 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Mar 25, 2025 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| May 30, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| May 29, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 24, 2024 | RFWR | P | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | Loading... |
| May 16, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| May 15, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 3, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 31, 2023 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Oct 27, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 26, 2023 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 001
Active chemical ingredients for use in the manufacture of pharmaceuticals for treating of gastrointestinal diseases, abdominal bloating, cardiovascular system diseases, gastroenteric system diseases, respiratory system diseases, immune and endocrine system diseases, chronic inflammatory diseases, skin diseases, urinary tract diseases, musculoskeletal disorders, metabolic diseases, ocular diseases, peripheral nervous disorders, ageing disorders, liver diseases, chronic fatigue syndrome, dietary supplements and dietetic preparations, all containing curcumin and boswellia; Chemical preparations for the manufacture of pharmaceuticals, dietary supplements and dietetic preparations, for treating of gastrointestinal diseases, abdominal bloating, cardiovascular system diseases, gastroenteric system diseases, respiratory system diseases, immune and endocrine system diseases, chronic inflammatory diseases, skin diseases, urinary tract diseases, musculoskeletal disorders, metabolic diseases, ocular diseases, peripheral nervous disorders, ageing disorders, liver diseases, chronic fatigue syndrome, all containing curcumin and boswellia; Chemical additives for use in the manufacture of food, all containing curcumin and boswellia.
Class 005
Pharmaceutical preparations for the treatment of gastrointestinal diseases, abdominal bloating, cardiovascular system diseases, gastroenteric system diseases, respiratory system diseases, immune and endocrine system diseases, chronic inflammatory diseases, skin diseases, urinary tract diseases, musculoskeletal disorders, metabolic diseases, ocular diseases, peripheral nervous disorders, ageing disorders, liver diseases, chronic fatigue syndrome diseases, all containing curcumin and boswellia; dietary supplements and dietetic preparations, all containing curcumin and boswellia; Plant and herb extracts, other than essential oils, for medicinal purposes, all containing curcumin and boswellia.
Additional Information
Design Mark
The mark consists of an outline of a mustard yellow square with the terms CURCUMIN in black at the top right of the square, the term BOSWELLIA in black under the bottom left edge of the square, the letters CU in bold black and large lettering, on the left upper edge of the square, and finally the letter BO in bold black and larger lettering on the bottom right edge of the square.
Color Claim
The color(s) black and mustard yellow is/are claimed as a feature of the mark.
Classification
International Classes
001
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"CURCUMIN" and "BOSWELLIA"